Pan Chi, Ge Lan, Zhang Huifeng, Sang Kai, Zhou Jian, Yi Tongbo, Ni Qingtao
Department of General Surgery, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, Jiangsu, PR China.
Department of Pathology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, Jiangsu, PR China.
Heliyon. 2024 Jul 11;10(14):e34511. doi: 10.1016/j.heliyon.2024.e34511. eCollection 2024 Jul 30.
Breast cancer (BC) is the prevailing malignancy among women, with HER2 overexpression observed in 20-30 % of all BC, thereby serving as a prognostic indicator for unfavorable outcomes in affected individuals. There is a necessity to establish innovative treatment protocols to expand the therapeutic alternatives accessible for managing HER2-positive BC. In this study, we report a case of HER2-positive BC that was managed in our department using a combination of three targeted drugs (Trastuzumab, Pertuzumab and Pyrotinib) along with chemotherapy. The treatment resulted in a pathological complete response (pCR) and was observed to be well-tolerated, without any significant adverse reactions. Hence, the combination of Pyrotinib and Dual HER2 blockade treatment shows promise as a neoadjuvant therapy for locally advanced HER2-positive BC to achieve a pCR in surgery. Nevertheless, this conclusion necessitates additional validation via meticulously designed clinical research investigations encompassing larger patient populations.
乳腺癌（BC）是女性中最常见的恶性肿瘤，在所有乳腺癌中，20%-30%观察到HER2过表达，因此可作为受影响个体不良预后的一个预后指标。有必要建立创新的治疗方案，以扩大可用于治疗HER2阳性乳腺癌的治疗选择。在本研究中，我们报告了1例HER2阳性乳腺癌病例，该病例在我们科室采用三种靶向药物（曲妥珠单抗、帕妥珠单抗和吡咯替尼）联合化疗进行治疗。治疗产生了病理完全缓解（pCR），且观察到耐受性良好，没有任何显著的不良反应。因此，吡咯替尼与双重HER2阻断治疗联合作为局部晚期HER2阳性乳腺癌的新辅助治疗以在手术中实现pCR显示出前景。然而，这一结论需要通过精心设计的、纳入更大患者群体的临床研究进行进一步验证。
